is tirzepatide still in shortage FDA says of GLP-1 drug over Mounjaro will remain off shortage

Quick Answer: BPC-157 Dosage In supervised protocols, BPC-157 is commonly dosed at 250 to 500 mcg per day subcutaneously, sometimes split into two injections and placed near the area being treated when possible

Common cycles are 8 to 12 weeks on, then 4 to 8 weeks off, but protocols differ by peptide and clinical response

CUSTOMER REVIEWS FAQs What is the difference between Flatter Me and Flatter Me Fiber

We also do not know whether the effect applies to people without obesity, or which patients respond best

It has not been approved by any regulatory authority and is being evaluated in Phase 3 clinical trials [1][3]